Spotlight On... Indian hospitals pioneering use of 'eICUs' to combat doctor shortage; Hospitals hire Philips to predict fall risk for elderly patients; Withings launches personalized blood pressure app; and more...

Indian doctors recently saved the life of a 30-year-old woman by instructing an unspecialized doctor about chest compressions over Internet-enabled video. The country's private hospital chains such as Fortis and Apollo plan to expand the number of so-called eICU beds by about 20% a year, from about 3,000 beds right now. "We save about 25 lives a month," said Shamit Gupta, medical director at Fortis' eICU unit. More

@FierceMedDev: Sientra resumes U.S. sales of breast implants after Brazil manufacturing fallout. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: PhRMA kicks off new ad campaign to doctor pharma's tarred image. Article | Follow @EmilyWFierce

> Royal Philips ($PHG) has secured a contract with Henry Ford Health System to provide its LifeLine technology powered by predictive analytics engine CareSage to help identify elderly patients that are at-risk of falling over the 30-day after hospital discharge. This is its eighth such U.S. hospital deal by Philips in the last 6 months. More

> Withings has launched an app to offer personalized, algorithmic analysis of blood pressure data from in-home monitors, including its own. More

> CorMatrix Cardiovascular has nabbed FDA clearance for its Tyke, an infant or neonate implant for the repair of pericardial structures, a patch for intracardiac defects, septal defects and annulus repair, suture-line buttressing, and cardiac repair. More

Biotech News

@FierceBiotech: Amplyx ups its B round to $49.2M on the way to the clinical with an antifungal drug. Article | Follow @FierceBiotech

@JohnCFierce: Are the big M&A players in biopharma (like Sanofi/Gilead/Biogen) waiting out the bear market? More | Follow @JohnCFierce

@DamianFierce: Thesis of this BIO thing is that you can't put $ on life, but doesn't pricing onco drugs based on OS do just that? | Follow @DamianFierce

> Apellis pulls its IPO as biotech bears rampage on Wall Street. Item

> OrbiMed founder preaches patience amid a biotech slump. Report

> In wake of $1B Celgene deal, Juno sweetens 2015 bonuses for CEO, CFO. Article

Pharma News

@FiercePharma: Omega diet-aid ad banned in U.K.; summer slimming promos not 'socially responsible.' FiercePharmaMarketing article | Follow @FiercePharma

@CarlyHFierce: All I want is to hear two people pronounce "Praluent" the same way. $REGN | Follow @CarlyHFierce

> Top Senate Democrat grills HHS about opioid panel's alleged ties to industry. Article

> Sanofi's outlook less than sunny as key diabetes franchise continues to sag. Report

Pharma Manufacturing News

> Plant to manufacture yellow fever jab slated for Dakar. More

> FDA quality focus will definitely mean winners and losers, report says. Report

> Dr. Reddy's grows U.S. sales even in face of FDA action. Story

> Report says CMOs without U.S. facilities risk being left out of 'hot' market. Item

> Strides Shasun deals adds seventh plant to its African production network. Article

Pharma Asia News

> China Resources Pharmaceutical plans HK IPO. News

> Taiwan's outgoing leader touts biotech growth. Story

> Japan's Eisai surprises with API move. Item

> Japan continues to see generics as way to ease healthcare costs. Report

> Novo says China price pressures may go into 2017. Article

Drug Delivery News

> 'Crystal balls' in drug delivery could be stronger than liposomes. More

> Novartis signs with France's MedinCell for controlled-release injection tech. Story

> FDA says drug delivery devices need human factors validation testing. Item

> Struggling Unilife extends negotiating period with Amgen over partial takeover. Report

> Scilex aims to dethrone Endo in billion-dollar pain subsegment using novel transdermal patch. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.